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Background
Despite significant advances made in the prevention and
treatment of malaria in recent years, these successes con-
tinue to fall short of the World Health Organization
(WHO) goals for malaria control and elimination. For
elimination strategies to be effective, limited disease trans-
mission, achieved through rapid reduction in infectious
parasite reservoir and decreased gametocyte carriage, will
be critical. Artemisinin-based combination therapy (ACT)
forms the cornerstone of WHO-recommended treatment
for uncomplicated Plasmodium falciparum malaria, and in
combination with other effective interventions will
undoubtedly play a vital role in elimination programmes.
The gametocytocidal properties of ACTs are a bonus attri-
bute; there is epidemiological evidence of reductions in
malaria incidence and transmission in African regions
since the introduction of these agents. Many studies and
analyses have specifically investigated the effects of arte-
mether-lumefantrine (AL) on gametocyte carriage.
Materials and methods
A systematic review of 62 articles published between
1998 and January 2014 was done which compares effects
of AL on gametocyte carriage and malaria transmission
with other ACTs and non-ACTs. AL was assessed based
on its widespread usage of ACTs recommended by
WHO, in the treatment for uncomplicated P. falciparum
malaria in several African countries and the high number
of clinical trials that have evaluated the product. Impact
of AL on population gametocyte carriage and potential
future role of AL in malaria elimination initiatives are
also considered.
Results
The gametocytocidal effect of AL was proportionately
con-sis tent across the studies reviewed, despite inherent
difficulties in comparing data from a range of studies that
utilized different diagnostic approaches to assess baseline
gametocyte counts and differences in study designs. How-
ever, the specific place of AL is the subject of ongoing
research and will be dependent on its use in combination
with other intervention measures, rational use of the pro-
duct, interaction with other medicinal agents in situations
of malaria co-infections and comorbidities, and demo-
graphic differences. Use of ACTs like AL in malaria elimi-
nation strategies will therefore require balancing potential
increased roll out with rational use and protection against
resistance development.
Conclusion
AL (along with other ACTs) will continue to play a vital
role in treatment of malaria by rapidly clearing asexual
parasite load and reducing gametocyte carriage in both
symptomatic patients and asymptomatic carriers. Conse-
quently, AL, an ACT with this significant dual activity
on asexual and sexual parasite forms, can help shrink
the infectious parasite reservoir that will in turn reduce
infection of mosquitoes and ultimately minimize malaria
transmission.
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